New Shicoh Motor recently filed a listing application with the Hong Kong Stock Exchange, with CICC and Huatai International as joint sponsors. According to a Frost & Sullivan report, the company is China's largest optical image stabilization imaging motor supplier by 2024 revenue, holding a 20.1% market share. The prospectus shows the company achieved 2024 revenue of RMB 1.565 billion and swung to profitability with a net profit of RMB 105 million.
The Hang Seng TECH Index rose from 4,468.11 points to 5,515.98 points in 2025, achieving a full-year gain of 23.45%.According to New Spacetime Research statistics, the Hang Seng TECH Index currently comprises 30 constituents. In 2025, 22 stocks posted gains with an average increase of 61.63%. Three stocks doubled in value, with nearly half gaining over 50%. Eight stocks declined with an average drop of 15.89%, and five fell more than 10%.
On January 7, 2026, Pando Ethereum ETF (03085.HK) rose by more than 1%. This product is among the first batch of compliant spot Ethereum exchange-traded funds in Hong Kong
On January 7, 2026, Ssif Dce Iron Ore Futures Index Etf (03047.HK) rose more than 3%. This product tracks the Dalian Commodity Exchange Iron Ore Futures Price Index and is suitable for investors with strong risk tolerance, in-depth understanding of commodity price fluctuations, and who hope to participate in iron ore market speculation or asset allocation through low-threshold tools.
On January 7, 2026, CSOP Tesla Daily (-2x) Inverse Product (07366.HK) once rose by more than 7%. It achieves 2x inverse daily performance tracking of Tesla's stock price through swap contracts, and is suitable for investors with extremely strong risk tolerance, who are familiar with the characteristics of leveraged tools and can monitor market fluctuations in real time.
As of 14:40 on January 7, 2026, Global X Ai Infrastructure Etf (03401.HK) had risen by 1.34%. The fund focuses on the field of artificial intelligence infrastructure, covering segments such as data center operations, energy supply, and heat dissipation management. It is suitable for investors with high risk tolerance and confidence in the long-term development of the artificial intelligence industry
At 14:24 on January 7, 2026, Hang Seng China Enterprises Index ETF (02828.HK) fell by 1.20% and has achieved net capital inflows for 4 consecutive days, accumulating over 2 billion yuan. It is suitable for investors who can withstand high volatility and are long-term optimistic about China's mainland economic growth.
As of 14:11 on January 7, 2026, CSOP Hang Seng Biotech ETF (03174.HK) has increased by over 10% this year. The fund closely tracks the Hang Seng Biotechnology Index and covers leading biotech companies listed in Hong Kong such as WuXi Biologics and BeiGene.
At 13:46 on January 7, 2026, Global X China Little Giant ETF (02815.HK) rose nearly 2%. This product tracks the Solactive China Little Giant Index, focusing on specialized, sophisticated, distinctive, and novel "little giant" enterprises in China's A-share market, covering emerging technology industries such as new energy, semiconductors, and high-end manufacturing.
At 13:33 on January 7, 2026, Csop Saudi Arabia Etf (02830.HK) rose more than 2%. The FTSE Saudi Arabia Index mainly invests in large and medium-sized listed companies in Saudi Arabia, covering industries such as finance and energy. It is suitable for investors who lay out the Middle East market for a long time and pursue high dividend income and economic transformation dividends.
At 13:12 on January 7, 2026, Samsung CSI China Dragon Internet ETF (02812.HK) dropped more than 2%. The heavyweight stocks of the index tracked by this fund cover about 30 globally listed leading Chinese internet enterprises such as Tencent, Alibaba, and Meituan.
the Chinaamc Hang Seng Hong Kong Biotech Index ETF(03069.HK) staged a strong morning session. As of 10:05, the fund had jumped more than 2%, extending its five-day gain to 8.35%. It is now on track for a fourth consecutive daily advance.
As of 09:43 on January 7, 2026, The China-Korea Semiconductor ETF (513310) jumped 6.10%, aiming for its third consecutive gain, with the latest price at 3.13 yuan.
Hangzhou Diagens Biotechnology Co., Ltd. once again submitted an application for listing to the Hong Kong Stock Exchange on January 6. Relying on the world's largest parameter iMedImageTM medical imaging large model, the company firmly ranks as the leader in China's chromosome karyotype analysis market with a 30.6% market share.
After obtaining the general mandate from the shareholders' general meeting on November 26, 2025, GF SECannounced on January 6, 2026 that it intends to place 219 million new H-shares at HK$18.15 per share and issue HK$2.15 billion zero-coupon convertible bonds due 2027 with an initial conversion price of HK$19.82 per share. The total funds raised from the two items are expected to be approximately HK$6.113 billion, and the net proceeds are intended to be fully used for capital increase to overseas subsidiaries to support the development of international business. The placed shares account for approximately 12.87% of the existing H-shares. If the convertible bonds are fully converted, approximately 108 million H-shares can be issued, accounting for approximately 6.37% of the existing H-shares. The completion of both issuances is subject to the fulfillment of conditions such as listing approval and filing with the China Securities Regulatory Commission.
HUTCHMED announced that the Phase III stage of the ESLIM-02 study on its Syk inhibitor sostarlimab for the treatment of warm antibody autoimmune hemolytic anemia has met the primary endpoint, namely sustained hemoglobin response during the treatment period from Week 5 to Week 24. The study targets patients who relapsed or were refractory after previous standard treatments. The company plans to submit a new drug application for this indication to the National Medical Products Administration in the first half of 2026. The Phase III study of sostarlimab for the treatment of immune thrombocytopenia has also achieved positive results, and the company similarly plans to resubmit a new drug application for this indication in the first half of 2026.